Skip to Content

Kepivance Approval History

  • FDA approved: Yes (First approved December 15th, 2004)
  • Brand name: Kepivance
  • Generic name: palifermin
  • Dosage form: Injection
  • Company: Amgen Inc.
  • Treatment for: Mucositis

Kepivance (palifermin) is a recombinant human keratinocyte growth factor indicated to decrease the incidence and duration of severe oral mucositis.

Development History and FDA Approval Process for Kepivance

Dec 15, 2004Approval Kepivance Amgen Inc. - Treatment for Severe Oral Mucositis in Cancer Patients
Jun 24, 2004Amgen Submits Biologics License Application for FDA Approval of Palifermin

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.